Skip to main page content

Dr. Shaheer Aboobaker

Scientific Planning Committee - Co-Developed Symposium
Participates in 2 items

Dr. Aboobaker is a fellowship trained retina specialist, having completed a 2-year Vitreoretinal fellowship at the University of Toronto. He obtained his medical degree at the University of KwaZulu Natal in South Africa and completed his residency at the prestigious University of Cape Town. While at the University of Cape Town, Dr. Aboobaker was awarded the Ophthalmological Society Medal for academic achievement by the Fellowship of Ophthalmologists of South Africa. Dr. Aboobaker joined the world renowned team at the Toronto Retina Institute in 2018 and has been working there since.

Dr. Aboobaker's academic and research interests include advancements in technology and innovative treatment options. He is the principal investigator in the CSR 2RT trial, assessing the time to recovery of nanosecond laser in the setting of acute CSR. He is also a sub-investigator in numerous ongoing trials. He has published several peer reviewed journal articles and has presented at both local and national meetings. He also established and spearheads the TRI Journal Club.

Dr. Aboobaker's passion for education and philanthropy led him to co-found the Young Professionals Bursary, a scholarship aimed at assisting disadvantaged students in South Africa. 

 

Financial disclosure: Dr. Aboobaker has/had an affiliation (financial or otherwise) with a commercial organization:

  1. Allergan
  2. Bayer
  3. Novartis
  4. REGENXBIO
  5. Roche

Sessions in which Dr. Shaheer Aboobaker participates

Saturday 17 June, 2023

Time Zone: (GMT-05:00) Eastern Time (US & Canada)
6:30 AM
6:30 AM - 8:00 AM | 1 hour 30 minutes
Co-Developed Symposium

*Breakfast to be served from 6:00am* Learning Objectives: At the end of this session, participants will be able to: Outline the role of the Tie-2/ang pathway in DR and nAMDand how it may impact patient outcomesIdentify the most important biomarkerson structural OCT that can help predict treatmentresponse in DME and nAMDDiscuss r...

7:10 AM